Systematic review / meta-analysis / 2019
Vitamin D supplementation did not significantly affect PSA change, PSA response, or mortality in controlled trials of prostate cancer patients.
A systematic review and meta-analysis evaluated 22 clinical trials (16 before-after studies and 6 randomized controlled trials) investigating vitamin D supplementation in patients with prostate cancer. In controlled clinical trials, vitamin D supplementation did not significantly differ from placebo for PSA change from baseline (WMD=-1.66 ng/ml, 95% CI: -0.69 to 0.36, p=0.543), PSA response proportion (RP=1.18, 95% CI: 0.97 to 1.45, p=0.104), or mortality (RR=1.05, 95% CI: 0.81 to 1.36, p=0.713). In single-arm trials, 19% of enrolled patients achieved at least a 50% reduction in PSA by the end of treatment (95% CI: 7% to 31%, p=0.002). The authors concluded that prostate cancer patients do not appear to benefit from high-dose vitamin D supplementation and it should not be recommended for treatment.
- Study type
- Systematic review and meta-analysis of clinical trials
- Who was studied
- Patients with prostate cancer across 22 studies (16 before-after, 6 RCTs)
- What was measured
- PSA change from baseline, PSA response proportion, mortality, side effects
THE PAPER
The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.
Shahvazi S, Soltani S, Ahmadi SM, de Souza RJ, Salehi-Abargouei A. Horm Metab Res, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.